昭和大学

腫瘍分子生物学研究所

Publications

業績

2016年度

原著論文

Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y: Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm. Res., 33(2), 269-282 (2016). Shibata T, Ebata T, Fujita K, Shimokata T, Maeda O, Mitsuma A, Sasaki Y, Nagino M, Ando Y: Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Cancer Sci., 107(2), 168-172 (2016). Hirose T, Fujita K, Kusumoto S, Oki Y, Murata Y, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohmori T, Sasaki Y: Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer, 93, 69-76 (2016). Okabe T, Ogura T, Yoshimura T, Tanaka Y, Toyoda H, Fujita K, Sasaki Y: Bioequivalence studies of a generic formulation (SW651K) to the brand drug S-1 in tumor-bearing rat models. J. Bioequiv. Availab., 8(3), 112-117 (2016). Matsunaga M, Kaneta T, Miwa K, Ichikawa W, Fujita K, Nagashima F, Furuse J, Kage M, Akagi Y, Sasaki Y: A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients. Oncol Lett., 12(1), 150-156 (2016). Saito K, Inoue Y, Ikegami Y, Nanbo I, Onozuka M, Sano K, Yoshida H, Sakamoto T, Tatebayashi E, Fujita K, Sasaki Y, Kitazawa T: Investigation of bioequivalence between brand-name and generic irinotecan products. Anticancer Res., 39, 5957-5964 (2016). Takata K, Fujita K, Kubota Y, Ishida H, Ichikawa W, Shimada K, Sekikawa T, Taki-Takemoto I, Kamei D, Iwai S, Sasaki Y: Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan. J. Pharm. Health Care Sci., Epub ahead of print (2016). Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y:Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Mol. Cancer Ther., 15(12), 3040-3054 (2016). Ito H, Sato J, Tsujino Y, Yamaguchi N, Kimura S, Gohda K, Ito S, Murakami K, Onimaru M, Ohmori T, Ishikawa F, Inoue H.: Long-term prognostic impact of circulating tumour cells in gastric cancer patients. World J. Gastroenterol., 22(46), 10232-10241 (2016). Ito H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H.: Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer. Oncol. Lett., 12(6), 4720-4726 (2016). Toba-Ichihashi Y, YamaokaT, Ohmori T, Ohba M: Up-regulation of Syndecan-4contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells. Biochem. Biophys. Rep., 5, 1-7 (2016)

総説

藤田健一:併存疾患を有する高齢がん患者への対応-polypharmacy.Cancer Board Square, 2(2), 64-68 (2016). 中島美紀,藤田健一,佐々木康綱:日本人におけるmicroRNA-SNP 解析:分子標的薬の個別化療法最適化に向けて.臨床薬理の進歩(Recent advances in clinical pharmacology), in press (2016).